Introduction
Antimicrobial resistance remains a global threat to public health. In groundbreaking new research performed by the teams of Weingarth (University of Utrecht) and Schneider (University of Bonn), clovibactin has been unveiled as a potent new antibiotic sourced from previously uncultivated soil bacteria.[1] This remarkable compound demonstrates unparalleled efficacy against drug-resistant Gram-positive bacterial pathogens, while exhibiting an absence of detectable resistance.
Chemical Structure of Clovibactin
The chemical structure of clovibactin, shown below, is a combination of L- and D-amino acids. It consists of an octapeptide backbone (L-Phe-D-Leu-D-Lys-L-Ser-D-Hyn-L-Ala-L-Leu-L-Leu), where the D-Hyn5 and L-Leu8 amino acids are joined via an ester linkage to form the macrocycle. The amino acid residue Hyn (3-hydroxyasparagine or β-hydroxyasparagine) is a modified asparagine amino acid, which appears in posttranslational modification of cbEGF-like domains that can occur in humans and other Eukaryotes. Clovibactin is possibly the most exciting depsipeptide antibiotic since the discovery of teixobactin in 2015.[2]
Unraveling the Mode of Action
Clovibactin's unique mode of action was unveiled through meticulous scientific investigation, which employed biochemical assays, solid-state nuclear magnetic resonance and atomic force microscopy. This antibiotic disrupts cell wall synthesis by precisely targeting the pyrophosphate groups of critical peptidoglycan precursors, including C55PP, lipid II, and lipid IIIWTA.[1]
A Masterful Adaptation
Clovibactin employs an extraordinary hydrophobic interface, which envelopes pyrophosphate groups with precision and deftly navigates the variable structural components of peptidoglycan precursors.[1] This fascinating mechanism underpins the antibiotic's resistance-evading prowess.
Sequestration and Supramolecular Fibrils
The key to clovibactin's selective and efficient binding lies in its ability to sequester precursors within supramolecular fibrils. These specialized structures exclusively form on bacterial membranes hosting lipid-anchored pyrophosphate groups, further enhancing the antibiotic's targeted efficacy.[1]
Conclusion
The revelation of clovibactin may mark a pivotal milestone in the battle against antimicrobial resistance. Its remarkable efficacy and novel mode of action offer hope for treatments that can irradicate bacterial threats without succumbing to the specter of resistance.
References
R. Shukla et al. 'An antibiotic from an uncultured bacterium binds to an immutable target'. Cell, 2023, 186, 4059–4073. https://doi.org/10.1016/j.cell.2023.07.038
L. L. Ling et al. 'A new antibiotic kills pathogens without detectable resistance'. Nature, 2015, 517, 455–459. https://doi.org/10.1038/nature14098
Comments